SAN DIEGO – Allele-specific KRAS inhibitors are “the most exciting change coming down the pike for treating KRAS-mutant tumors in the near future,” Ferdinandos Skoulidis said at the sixth joint conference by the American Association for Cancer Research and the International Association for the Study of Lung Cancer meeting.
Transgene SA is quitting development of one of its lead therapeutic vaccines after a combination of the candidate, TG-4010, with chemotherapy and Opdivo missed its primary endpoint in a phase II trial evaluating the combination as a first-line treatment for certain advanced non-squamous non-small-cell lung cancers.
